Silverarc Capital Management’s Radiopharm Theranostics RADX Stock Holding History

Silverarc Capital Management’s Portfolio RADX Stock Details RADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$806K	Hold	187,406	–	–	0.08%	68
2025 Q4	$978K	Hold	187,406	–	–	0.14%	62
2025 Q3	$1.03M	Hold	187,406	–	–	0.14%	68
2025 Q2	$870K	Hold	187,406	–	–	0.16%	55
2025 Q1	$901K	Hold	187,406	–	–	0.18%	63
2024 Q4	$841K	Buy	+187,406	New	+$1.23M	0.18%	55

Other funds holding RADX

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Silverarc Capital Management's RADX Position: Q1 2026 in Review

Silverarc Capital Management held its Radiopharm Theranostics (RADX) position steady in Q1 2026 at 187,406 shares worth $806K. The position accounts for 0.08% of the portfolio, ranked #68.

Silverarc Capital Management first reported a position in RADX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.03M in Q3 2025. 7 funds tracked by Wall St. Rank hold RADX as of Q1 2026.

Silverarc Capital Management held 187,406 shares of Radiopharm Theranostics worth $806K as of Q1 2026.
Silverarc Capital Management left its Radiopharm Theranostics share count unchanged in Q1 2026.
Radiopharm Theranostics made up 0.08% of Silverarc Capital Management's portfolio in Q1 2026, its #68 holding.
Silverarc Capital Management first reported a position in Radiopharm Theranostics in Q4 2024 and has held it in 6 quarters since.
Silverarc Capital Management's Radiopharm Theranostics position peaked at $1.03M in Q3 2025.
7 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.